Cancer immunotherapy: moving beyond current vaccines.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 15340416.
- Also identified by PMC identifier 1435696.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Great progress has been made in the field of tumor immunology in the past decade, but optimism about the clinical application of currently available cancer vaccine approaches is based more on surrogate endpoints than on clinical tumor regression. In our cancer vaccine trials of 440 patients, the objective response rate was low (2.6%), and comparable to the results obtained by others. We consider here results in cancer vaccine trials and highlight alternate strategies that mediate cancer regression in preclinical and clinical models.
Medical subject headings
- Cancer Vaccines
- Immunotherapy
- Models, Immunological
- Neoplasm Metastasis
- Neoplasms